Evidence map›Paper›PMID 36526929›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Sexual dysfunction among gynecologic cancer survivors in a population-based cohort study.

Chun-Pin Chang, Christina M Wilson, Kerry Rowe, John Snyder, Mark Dodson, Vikrant Deshmukh, Michael Newman, Alison Fraser, Ken Smith, Ankita Date and 4 more

Open access · greenAbstract read
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Let's talk about sex: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology: clinical recommendations after pelvic radiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Chun-Pin Chang *Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, and Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA. esther.chang@utah.edu.
Christina M Wilson *School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.
Kerry RoweIntermountain Healthcare, Salt Lake City, UT, USA.
John SnyderIntermountain Healthcare, Salt Lake City, UT, USA.
Mark DodsonIntermountain Healthcare, Salt Lake City, UT, USA.
Vikrant DeshmukhUniversity of Utah Health Sciences Center, Salt Lake City, UT, USA.
Michael NewmanUniversity of Utah Health Sciences Center, Salt Lake City, UT, USA.
Alison FraserPedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Ken SmithPedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Ankita DatePedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Joseph B StanfordDivision of Public Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
David GaffneyDepartment of Radiation Oncology, University of Utah School of Medicine, and Huntsman Cancer Institute, Salt Lake City, UT, USA.
Kathi MooneyCollege of Nursing, and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Mia HashibeDivision of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, and Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA.
Huntsman Cancer Institute · USUniversity of Utah · USIntermountain Healthcare · USUniversity of Alabama at Birmingham · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Interdisciplinary Training in Cancer, Caregiving and End-of-Life CareT32NR013456 · NINR · UNIVERSITY OF UTAH · PI ELLINGTON, LEE A, MOONEY, KATHLEEN H · 2013 to 2022
$3.4M
Sharing statewide health data for genetic research (1 R01 RR021746-01A1)R01RR021746 · NCRR · UNIVERSITY OF UTAH · PI MINEAU, GERALDINE P · 2007 to 2009
$770k
Population-based Cohort of Endometrial Cancer Survivors in UtahR21CA185811 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2015 to 2016
$356k
Epidemiology of testicular cancer in the Utah populationR03CA159357 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2011 to 2012
$150k
NCATS NIH HHS UL1 TR002538NCI NIH HHS P30 CA042014NCI NIH HHS P30CA042014NCI NIH HHS R03 CA159357NCI NIH HHS R21 CA185811NCRR NIH HHS R01 RR0217NCRR NIH HHS R01 RR021746NINR NIH HHS T32 NR013456NINR NIH HHS T32NR013456
6 · The paper itself

Abstract

Treatment for gynecologic cancer is associated with sexual dysfunction, which may present during and/or after treatment. The aim of this study was to investigate the risk of sexual dysfunction among gynecologic cancer survivors compared to cancer-free women in a population-based cohort study. We identified a cohort of 4863 endometrial, ovarian, and cervical cancer survivors diagnosed between 1997 and 2012 in the Utah Cancer Registry. Up to five cancer-free women were matched to cancer survivors (N = 22,693). We used ICD-9 codes to identify sexual dysfunction. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for sexual dysfunction with adjustment for potential confounders. Approximately 6.6% of gynecologic cancer survivors had sexual dysfunction diagnoses 1-5 years after cancer diagnosis. Gynecologic cancer survivors had higher risks of overall sexual dysfunction (HR: 2.51, 95% CI: 2.16, 2.93), dyspareunia (HR: 3.27, 95% CI: 2.63, 4.06), and vaginal dryness (HR: 2.63, 95% CI: 2.21, 3.12) compared to a general population of women, 1-5 years after cancer diagnosis. Sexual dysfunction was associated with advance cancer stage (HR

Indexed as

Cancer SurvivorsGenital Neoplasms, FemaleSexual Dysfunction, PhysiologicalCohort StudiesFemaleHumansSurvivorsCervical cancerEndometrial cancerGynecologic cancerOvarian cancerSexual dysfunctionSexual healthSurvivors

Identifiers

PMID36526929
PMCPMC9850804
OpenAlexW4312018301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.